Market Exclusive

CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) Files An 8-K Other Events

CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) Files An 8-K Other Events

Item 8.01.Other Events.

On December 14, 2016, CytomX Therapeutics, Inc. issued a press
release announcing that the U.S. Food and Drug Administration
(FDA) has cleared the companys Investigational New Drug (IND)
application for its lead program, CX-072, a wholly-owned
PD-L1-targeting Probody therapeutic for the treatment of cancer.
The full text of the press release is furnished as Exhibit 99.1
hereto.

Item 9.01

Financial Statements and Exhibits.

Reference is made to the Exhibit Index attached hereto

About CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX)
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets. A Probody therapeutic consists of three components produced as a single protein by standard antibody production methodology: an active anti-cancer antibody, a mask for the antibody and a protease-cleavable linker. Its Probody product candidate, CX-072, is directed against programmed death-ligand 1 (PD-L1). CX-072 is based on a monoclonal antibody targeting PD-L1. Its product candidate, CX-2009, is directed against the target CD-166. It is developing a programmed cell death protein 1 (PD-1) Probody therapeutic as an additional approach to block the PD-L1/PD-1 pathway. It is also conducting Integrin alpha-3 PDC program. CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) Recent Trading Information
CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) closed its last trading session down -0.05 at 11.48 with 126,685 shares trading hands.

Exit mobile version